Latest Period
Q1 2026
Security Snapshot
RECURSION PHARMACEUTICALS, INC. - Class A Stock (RXRX) Institutional Ownership
CUSIP: 75629V104
13F Institutional Holders and Ownership History from Q1 2019 to Q1 2026
Institutions Reporting
330
Shares (Excl. Options)
336,117,005
Price
$3.07
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Class A Stock
- Symbol
- RXRX on Nasdaq
- Shares outstanding
- 525,302,736
- Reported price per share
- $3.15
- Price from insider filings
- $3.15
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 336,117,005
- Total reported value
- $1,031,963,424
- Portfolio coverage rank
- 0%
- Share change
- +10,772,611
- Value change
- +$24,624,438
- Number of holders
- 330
Security identity
Issuer context
Latest holder snapshot
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- RXRX - RECURSION PHARMACEUTICALS, INC. - Class A Stock is tracked under CUSIP 75629V104.
- 330 institutions reported positions in Q1 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 332 to 330 between Q4 2025 and Q1 2026.
- Reported value moved from $1,326,293,585 to $1,031,963,424.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 330 institutions filings for Q1 2026.
Security key
75629V104
Latest holder period
Q1 2026
13F holders
330
13D/G owners
5
CIK / CUSIP context first
Open Q1 2026 holders
RXRX full holder history
RECURSION PHARMACEUTICALS, INC. SEC filings
RECURSION PHARMACEUTICALS, INC. company facts
RECURSION PHARMACEUTICALS, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 75629V104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
RXRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 7.2% | +18% | $116,112,917 | +$44,162,444 | 37,821,797 | +61% | BlackRock, Inc. | 31 Mar 2026 |
| ARK Investment Management LLC | 7.2% | -15% | $152,625,941 | +$20,329,177 | 37,316,856 | +15% | ARK Investment Management LLC | 31 Dec 2025 |
| BAILLIE GIFFORD & CO | 4.6% | $97,239,635 | 23,774,972 | BAILLIE GIFFORD & CO | 31 Dec 2025 | |||
| RA CAPITAL MANAGEMENT, L.P. | 2% | $44,187,549 | 7,725,096 | RA Capital Management, L.P. | 31 Dec 2024 | |||
| Kim Yohan | 5.9% | $1,530,100 | 267,500 | Yohan Kim | 04 Apr 2025 |
As of 31 Mar 2026, 330 institutional investors reported holding 336,117,005 shares of RECURSION PHARMACEUTICALS, INC. - Class A Stock (RXRX). This represents 64% of the company’s total 525,302,736 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
54%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.2% | 43,192,306 | +11% | 0% | $132,600,379 |
| ARK Investment Management LLC | 7.7% | 40,212,769 | +7.8% | 0.96% | $123,453,202 |
| STATE STREET CORP | 5.4% | 28,490,638 | +12% | 0% | $87,466,259 |
| BAILLIE GIFFORD & CO | 4.5% | 23,675,407 | -0.42% | 0.07% | $72,683,499 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.3% | 22,759,100 | 0% | 0% | $69,870,437 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 22,244,387 | 0% | 0% | $68,290,268 |
| SOFTBANK GROUP CORP. | 2.6% | 13,636,515 | 0% | 0.37% | $41,864,101 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 12,275,084 | +12% | 0% | $37,692,773 |
| MIC Capital Management UK LLP | 1.8% | 9,644,032 | 0% | 8.4% | $29,607,180 |
| GOLDMAN SACHS GROUP INC | 1.2% | 6,065,661 | +176% | 0% | $18,621,579 |
| Data Collective IV GP, LLC | 1.1% | 5,941,120 | 0% | 33% | $18,239,238 |
| Lingotto Investment Management LLP | 1.1% | 5,881,738 | +19% | 0.36% | $18,056,936 |
| Amova Asset Management Americas, Inc. | 1% | 5,419,221 | -13% | 0.23% | $16,582,816 |
| Sumitomo Mitsui Trust Group, Inc. | 1% | 5,419,221 | -13% | 0.01% | $16,637,008 |
| UBS Group AG | 0.97% | 5,101,237 | +38% | 0% | $15,660,798 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.8% | 4,225,277 | -3.9% | 0.02% | $12,971,600 |
| TWO SIGMA INVESTMENTS, LP | 0.77% | 4,066,315 | +32% | 0.01% | $12,483,587 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 0.77% | 4,023,398 | -1.3% | 0% | $12,351,832 |
| NORTHERN TRUST CORP | 0.76% | 3,968,411 | +15% | 0% | $12,183,022 |
| DCVC Opportunity Fund II GP, LLC | 0.75% | 3,951,141 | 0% | 87% | $12,130,003 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.73% | 3,808,798 | -4.7% | 0% | $11,693,010 |
| VANGUARD FIDUCIARY TRUST CO | 0.67% | 3,514,983 | 0% | 0% | $10,790,998 |
| MARSHALL WACE, LLP | 0.55% | 2,876,928 | +1170% | 0.01% | $8,832,169 |
| MILLENNIUM MANAGEMENT LLC | 0.5% | 2,612,277 | +75% | 0.01% | $8,019,690 |
| FIRST TRUST ADVISORS LP | 0.5% | 2,610,726 | +15% | 0.01% | $8,014,928 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
29
Latest
Q1 2026
Rows shown
1-25 of 29
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 336,117,005 | $1,031,963,424 | +$24,624,438 | $3.07 | 330 |
| 2025 Q4 | 324,262,108 | $1,326,293,585 | +$25,282,966 | $4.09 | 332 |
| 2025 Q3 | 324,190,091 | $1,581,950,465 | +$66,787,219 | $4.88 | 321 |
| 2025 Q2 | 310,182,949 | $1,569,493,304 | +$26,510,398 | $5.06 | 329 |
| 2025 Q1 | 304,244,163 | $1,609,644,830 | -$29,277,099 | $5.29 | 330 |
| 2024 Q4 | 304,544,141 | $2,058,776,356 | +$268,240,445 | $6.76 | 310 |
| 2024 Q3 | 264,392,743 | $1,743,289,324 | +$54,064,157 | $6.59 | 262 |
| 2024 Q2 | 251,836,128 | $1,888,574,788 | +$298,622,706 | $7.50 | 264 |
| 2024 Q1 | 212,714,397 | $2,120,552,518 | +$62,304,334 | $9.97 | 242 |
| 2023 Q4 | 206,501,532 | $2,035,976,922 | +$306,507,294 | $9.86 | 194 |
| 2023 Q3 | 152,228,034 | $1,164,429,792 | +$189,175,887 | $7.65 | 189 |
| 2023 Q2 | 127,547,789 | $952,749,699 | +$12,757,431 | $7.47 | 155 |
| 2023 Q1 | 126,153,704 | $841,388,403 | +$14,595,249 | $6.67 | 157 |
| 2022 Q4 | 123,786,379 | $954,397,559 | +$134,707,594 | $7.71 | 144 |
| 2022 Q3 | 113,749,582 | $1,210,251,991 | +$75,709,491 | $10.64 | 141 |
| 2022 Q2 | 106,463,853 | $861,094,172 | +$96,496,440 | $8.14 | 130 |
| 2022 Q1 | 95,043,699 | $680,250,380 | -$12,978,444 | $7.16 | 124 |
| 2021 Q4 | 94,346,907 | $1,616,473,942 | +$295,962,917 | $17.13 | 122 |
| 2021 Q3 | 54,909,739 | $1,262,978,377 | +$181,552,159 | $23.01 | 82 |
| 2021 Q2 | 46,974,230 | $1,714,334,294 | +$1,714,333,294 | $36.50 | 75 |
| 2021 Q1 | 30 | $1,000 | $33.33 | 1 | |
| 2020 Q4 | 30 | $1,000 | $33.33 | 1 | |
| 2020 Q3 | 30 | $1,000 | $33.33 | 1 | |
| 2020 Q2 | 30 | $1,000 | $33.33 | 1 | |
| 2020 Q1 | 30 | $1,000 | $33.33 | 1 |